Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 4/20 | 0.57 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5274170 | 1.00 | CCR5 (0.57) | CCR5ROCK2DRD2DRD3KMT2A | |
| SCHEMBL5266055 | 0.87 | CCR5 (0.50) | CCR5DRD2DRD3SIGMAR1FUCA1 | |
| SCHEMBL14224261 | 0.87 | CCR5 (0.50) | CCR5DRD2DRD3SIGMAR1FUCA1 | |
| SCHEMBL7827978 | 0.87 | CCR5 (0.50) | CCR5DRD2DRD3SIGMAR1FUCA1 | |
| SCHEMBL4105592 | 0.87 | CCR5 (0.50) | CCR5DRD2DRD3SIGMAR1FUCA1 | |
| SCHEMBL7817702 | 0.87 | CCR5 (0.50) | CCR5DRD2DRD3SIGMAR1FUCA1 | |
| SCHEMBL3646250 | 0.85 | CCR5 (0.42) | CCR5DRD2DRD3SIGMAR1FUCA1 | |
| SCHEMBL6902319 | 0.85 | CCR5 (0.42) | CCR5DRD2DRD3SIGMAR1FUCA1 | |
| SCHEMBL1713447 | 0.85 | CCR5 (0.42) | CCR5DRD2DRD3SIGMAR1FUCA1 | |
| SCHEMBL6904062 | 0.83 | DRD4 (0.41) | CCR5DRD2DRD3SIGMAR1FUCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831210-A1 | 8-AZA-BICYCLO[3.2.1]OCTANE DERIVATIVES WITH AN ACTIVITY ON CHEMOKINE CCR5 RECEPTORS | Pfizer Limited (GB) | 2007-09-12 | — | — | EP | disclosed |
| US-7125887-B2 | Pyrrolidine modulators of CCR5 chemokine receptor activity | MERCK & CO., INC. (US) | 2006-10-24 | — | — | US | disclosed |
| WO-2006067584-A1 | 8-AZA-BICYCLO (3.2.1) OCTANE DERIVATIVES WITH AN ACTIVITY ON CHEMOKINE CCR5 RECEPTORS | PFIZER LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
| US-20040087552-A1 | Pyrrolidine modulators of ccr5 chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2004-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087552-A1 | Pyrrolidine modulators of ccr5 chemokine receptor activity | CCR5, CCR1, CXCR1 | CCR5 1/4885ROCK2 1987/4885DRD2 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.